IL6 and chronic myelogenous leukemia, BCR-ABL1 positive: Targeting inflammatory signals mitigates clonal hematopoiesis in TET2-mutated preleukemic stem and progenitor cells20, blocking IL-6 signaling delays chronic myeloid leukemia development21 and interfering in the JAK/STAT pathway shows anti-leukemic activity in AML in vitro7, which prove the feasibility of targeting the inflammasome in myeloid diseases.